Enalkiren

This classification denotes an antihypertensive agent with the molecular formula C35H56N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0U7YZ42Z47, chemically known as l-histidinamide, n-(3-amino-3-methyl-1-oxobutyl)-o-methyl-l-tyrosyl-n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1s-(1r*,2s*,3r*))- but generally known as enalkiren, which bears US NIH Compound Identifier 60594. European Medicines Agency schedules Enalkiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06516MIG. The term ENALKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). ENALKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enalkiren under HS 29332990 and SITC 51573. As of Q4 2014, ENALKIREN remains the US FDA Preferred Term for this commodity. Enalkiren bears US NLM identifiers UMLS ID C0059089 and NCI Concept Code C87729. SMILES: OC(C(NC(=O)C(NC(=O)C(NC(=O)CC(N)(C)C)Cc1ccc(OC)cc1)Cc1[nH]cnc1)CC1CCCCC1)C(O)CC(C)C.